Advertisement
Home2024-01-11T09:26:42-05:00

Top Story

  • Health Policy
    February 21st, 2024

    Three pharmaceutical companies—GSK, Kaléo, and Amneal—have agreed to delist several patents in response to the Federal Trade Commission's (FTC) November challenge, aiming to increase competition by addressing alleged misuse of the patent system. GSK will remove 17 patents related to its inhalers, while Kaléo and Amneal [...]

HEOR

Advertisement

Featured Webinars

Handpicked Promotions & Highlights

Latest in Catalyst News powered by BioPharmCatalyst

03/28/2024 04:45 PM ET

Reviva Pharmaceuticals Holdings RVPH date announcement

Now that the Phase 3 trial of Brilaroxazine - (RECOVER) is completed, Reviva Pharmaceuticals Holdings will announce their top-line results on December 31, 2024. As of now, the drug has a 60.5% chance of moving [...]

Read More
03/28/2024 04:45 PM ET

Avalo Therapeutics MIST date announcement

Milestone Pharmaceuticals has an announcement scheduled for June 30, 2024 regarding their recent NDA Filing trial of Etripamil - (RAPID). The community is currently bullish on the prospects of progression, as all four community members [...]

Read More
03/28/2024 04:45 PM ET

Atara Biotherapeutics ATRA earnings announcement

Atara Biotherapeutics revealed their most recent quarterly earnings data, in which both revenue and EPS ended up lower than estimates. EPS was estimated to be -$0.48, but the actual figure came in at -$0.56.

[...]

Read More
03/28/2024 04:45 PM ET

Candel Therapeutics CADL earnings announcement

Candel Therapeutics revealed their most recent quarterly earnings data, in which both revenue and EPS ended up lower than estimates. EPS, at -$0.38, was the biggest surprise for the quarter, as it missed [...]

Read More

Receive essential insights, resources and content direct to your inbox

Hit subscribe to stay informed!

Go to Top